SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-111-WQH-NLS, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased or otherwise acquired Fate securities during the Class Period, you have until March 22, 2023 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Fate is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies to treat cancer and immune disorders.

On April 2, 2020, after the market closed, Fate announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment (the “Janssen Collaboration Agreement”). In addition, Fate was eligible for up to $3 billion in various milestone payments and double-digit royalties on any net sales from the collaboration. On the news, Fate’s stock price jumped 8.8% in trading on April 3, 2020.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement’s on Fate’s long-term clinical and commercial profitability; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On January 5, 2023, after the markets closed, Fate issued a press release announcing that it had terminated the Janssen Collaboration Agreement. Specifically, the Company disclosed that it was “not able to align with Janssen on their proposal for continuation of our collaboration, where two product candidates targeting high-value, clinically-validated hematology antigens were set to enter clinical development in 2023[.]” As a result of the termination, Fate revealed that all licenses and other rights granted pursuant to the Janssen Collaboration Agreement would terminate, that it would reduce its headcount to about 220 employees in Q1 2023, and that it would discontinue several of its natural cell killer programs in various cancers, including FT516 and FT538 NK cell programs in acute myeloid leukemia, FT516 and FT596 NK cell programs in B-cell lymphoma, and FT538 and FT536 NK cell programs in solid tumors.

On this news, Fate’s stock price fell $6.76 per share, or 61.45%, to close at $4.24 per share on January 6, 2023.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:

Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980



SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

TIN LIÊN QUAN

Notice of Filing Securities Class Action Against Global

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. has filed a federal securities class action in the United States District Court...

CRBU Class Action Lawsuit Announced: Johnson Fistel

SAN DIEGO, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on...

BROS EQUITY ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM,

NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on...

Vertex Energy, Inc. (VTNR) Shareholder Notice: Robbins LLP

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons...

Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or...

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Atlassian

NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Atlassian...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kornit Digital

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kornit...

SUNL FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL,

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sunlight...

THỦ THUẬT HAY

Hướng dẫn cách tăng tốc độ tắt máy tính nhanh hơn

Thông thường nếu bạn muốn tắt máy máy tính, bạn chỉ cần một vài thao tác nhấp chuột là có thể “cho phép” Windows ngừng hoạt động và sau đó tiến hành ngắt kết nối điện cho máy tính. Nhưng đôi khi, bạn sẽ thấy một thông

Cách chia sẻ file qua mã QR trên Samsung với Android 12 cực nhanh

Với One UI 4.0 (Android 12) thì Samsung đã thêm phần Chia sẻ bằng mã QR trong Quick Share. Bài viết sau đây mình sẽ hướng dẫn các bạn cách chia sẻ file qua mã QR trên Samsung...

MacBook bị nóng?Cách giảm nhiệt nhanh chóng mà hiệu quả

Có rất nhiều nguyên nhân khiến MacBook bị nóng như xung đột phần mềm, chơi các tựa game, sử dụng tác vụ nặng trong thời gian dài,...

Microsoft vô hiệu hóa VBScript trên IE 11 cho các trang web trên Internet Zone và Restricted Sites

Microsoft sẽ vô hiệu hóa VBScript trên IE 11 cho các trang web trên Internet Zone và Restricted Sites Zone để người dùng duyệt web an toàn hơn và tốt hơn. Sau khi vô hiệu hóa VBScript trên trình duyệt, IE 11 IE11 sẽ

Làm thế nào để kiểm tra và phát hiện các sự cố RAM và phần cứng trên máy tính Windows của bạn?

Windows Memory Diagnostic là một trong những công cụ miễn phí để kiểm tra tình trạng RAM trên máy tính của người dùng. Để hiểu rõ hơn về cách sử dụng, cũng như cách kiểm tra tình trạng RAM trên máy tính của mình, mời

ĐÁNH GIÁ NHANH

Đánh giá LG V40 ThinQ: Không mang lại sự thỏa mãn với giá 1.000 USD

Mặc dù G-series vẫn là dòng smartphone flagship cao cấp chính của LG, tuy nhiên dòng smartphone V-series cũng luôn nhận được lượng quan tâm rất lớn. LG V30 ra mắt năm ngoái là sự thành công ngoài mong đợi, một chiếc

Đánh giá toàn diện Apple iPhone X và Google Pixel 2 XL

Cả hai điện thoại có giá khởi điểm cao, 849 USD với Pixel 2 XL và 999 USD với iPhone X. Kích thước màn hình của chúng cũng tương tự, gồm 5,8 inch với iPhone X và 6 inch với Pixel 2 XL.

Subaru Levorg đạt đánh giá an toàn năm sao tại Úc

Subaru Levorg đã được đánh giá năm sao trong chương trình đánh giá xe mới Australia (Australasian New Car Assessment Program - ANCAP), với tổng điểm 35,85/37 điểm. Mẫu xe wagon vừa ra mắt mới đây tại...